SCHEMBL4124875

SCHEMBL4124875

COc1cccc(C(O)c2cc(Cl)ccc2NC(=O)O)c1OC(F)F

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LPAR1 Q92633 4/20 0.45
GAA P10253 3/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
ALDH1A1 P00352 5/20 0.39
NPSR1 Q6W5P4 4/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
GRIK1 P39086 1/20 0.39
KDM4E B2RXH2 3/20 0.39
LMNA P02545 3/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
FDFT1 P37268 1/20 0.38
MAPT P10636 3/20 0.38
KMT2A Q03164 3/20 0.38
MEN1 O00255 2/20 0.38
IGF1R P08069 1/20 0.37
KCNMA1 Q12791 1/20 0.37
HIF1A Q16665 1/20 0.37
TDP1 Q9NUW8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13775845 0.87 LPAR1 (0.41) LPAR1GAASMN1; SMN2ALDH1A1NPSR1
SCHEMBL4122916 0.85 LPAR1 (0.56) LPAR1GAASMN1; SMN2ALDH1A1NPSR1
SCHEMBL4110722 0.85 SMN1; SMN2 (0.42) LPAR1GAASMN1; SMN2ALDH1A1NPSR1
SCHEMBL4129998 0.85 LPAR1 (0.48) LPAR1GAASMN1; SMN2ALDH1A1NPSR1
SCHEMBL4125868 0.85 LPAR1 (0.50) LPAR1GAASMN1; SMN2ALDH1A1NPSR1
SCHEMBL4123090 0.85 LPAR1 (0.50) LPAR1GAASMN1; SMN2ALDH1A1NPSR1
SCHEMBL4124228 0.83 LPAR1 (0.43) LPAR1GAASMN1; SMN2ALDH1A1NPSR1
SCHEMBL4116747 0.82 LPAR1 (0.45) LPAR1SMN1; SMN2ALDH1A1NPSR1L3MBTL1
SCHEMBL4134040 0.82 LPAR1 (0.49) LPAR1GAASMN1; SMN2ALDH1A1NPSR1
SCHEMBL4123117 0.80 FDFT1 (0.36) LPAR1GAASMN1; SMN2ALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090181942-A1 TRICYCLIC COMPOUNDS DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-07-16 US disclosed
EP-1939205-A1 TRICYCLIC COMPOUND Daiichi Sankyo Company, Limited (JP) 2008-07-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181942-A1 TRICYCLIC COMPOUNDS FDFT1, COASY, HMGCR LPAR1 345/4885GAA 922/4885SMN1; SMN2 4445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.